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Abstract
Background:Mechanical chest compression devices deliver high-quality chest compressions. Early data suggests that mechanical devices may be
superior to manual chest compressions in adults following an in-hospital cardiac arrest patients. To determine the feasibility of undertaking an
effectiveness trial in this population, we undertook a feasibility randomised controlled trial.
Methods: We undertook a multi-centre parallel group feasibility randomised controlled trial (COMPRESS-RCT). Adult in-hospital cardiac arrest
patients that were in a non-shockable rhythm were randomised in a 3:1 ratio to receive mechanical CPR (Jolfe AB/Stryker, Lund, Sweden) or ongoing
manual CPR. Recruitment was led by the clinical cardiac arrest team.
The primary study outcome was the proportion of eligible participants randomised in the study during site operational recruitment hours. Patients were
enrolled under a model of deferred consent. We report data using descriptive statistics, point estimates and 95% confidence intervals.
Results: Over a two-year period, we recruited 127 patients across five UK hospitals. We recruited 55.2% (95% CI 48.5%61.8%) of eligible study
participants in site operational recruitment hours.Most participantsweremale (n = 76, 59.8%)with ameanage of 72 (95%CI: 69.974.9) years.Median
arrest duration was 18 (IQR 1329) minutes. In patients randomised to mech-CPR, median time from CPR start to device deployment was 11 (IQR 7
15) minutes. ROSC was achieved in 27.6% (n= 35) participants and 4.7% (n= 6) were alive at 30-days.
Conclusion:COMPRESS-RCT identified important factors that preclude progression to an effectiveness trial ofmechanical CPR in the hospital setting
in the UK. Findings will inform the design of future in-hospital intra-arrest intervention trials.
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Background
In the UK, there are approximately 35,000 in-hospitals cardiac arrests
per year with an overall hospital survival of 18.4%.1 High-quality
cardiopulmonary resuscitation (CPR), defibrillation, and reversal of
the underlying cause are the mainstay of cardiac arrest treatment.2
However, delivery of high-quality CPR in clinical practice is often
challenging.35
Mechanical chest compression devices (mech-CPR) deliver high-
quality CPR.6 In out-of-hospital cardiac arrest, large randomised
controlled trials show that mech-CPR is not superior to manual CPR
(man-CPR).79 As such, current guidelines recommend against the
routineuseofmech-CPR.10 In contrast, researchonmech-CPRuse in
the hospital setting has been limited. Small randomised controlled
trials and observational studies have produced very low-certainty
evidence that mech-CPR use in the hospital setting is associated with
improved clinical outcomes.11
Based on evidence of mech-CPR use at in-hospital cardiac arrest
and uncertainty regarding its effectiveness, we identified a need for a
clinical trial to evaluate the effect of the routine use of mech-CPR,
compared with man-CPR in adults that sustain an in-hospital cardiac
arrest.12,13 In contrast to out-of-hospital cardiac arrest, there have
been relatively few trial of intra-arrest interventions for in-hospital
cardiac arrests.14 As such,wedecided to first test the deliverability of a
mech-CPR trial in a feasibility trial.
Methods/design
We conducted a multi-centre parallel group randomised controlled
feasibility trial across fiveUKhospitals.We randomised in a 3:1 ratio to
either mech-CPR or man-CPR. The trial objective was to assess how
feasible itwould be todeliver aneffectivenessmech-CPR trial in the in-
hospital cardiac arrest population.
The trial was approved by the West Midlands  Coventry and
WarwickshireResearchEthicsCommittee (16/WM/0299). TheHealth
Research Authority Confidentiality Advisory Group approved the
processing and transfer of data without consent, under The Health
Service (Control of Patient Information) Regulations 2002 (16/CAG/
0088). We prospectively registered the trial with the ISRCTN Trial
Registry (ISRCTN08233942). We published the protocol in an open-
access journal.15 A National Institute for Health Research Post-
Doctoral Research Fellowship (PDF-2015-08-109) funded the trial.
We conducted in accordance with Medical Research Council
(MRC) Good Clinical Practice guidelines, national legislation and
University of Warwick Clinical Trials Unit Standard Operating
Procedures. The University of Warwick sponsored the trial.
During the trial, we amended the primary outcome from proportion
of eligible patients randomised to proportion of eligible patients
randomised during operational recruitment hours. This change was
made on 21st March 2018 (midway through trial recruitment) due to
the challenges experienced by some sites in recruiting 24/7. Our
ISCTRN registration records this change.
Eligibility criteria
Adults (age 18) that sustained an in-hospital cardiac arrest were
eligible for inclusion if the cardiac arrest was attended by an
emergency team trained in the use of mech-CPR and the patient was
in a non-shockable rhythm at the point of the study eligibility
assessment. Key exclusion criteria included known pregnancy,
prisoners, known previous study participation, and cases where
mech-CPRwas contraindicated (for example, patient size) or required
as part of routine clinical care (for example, cardiac arrest during
coronary angiography).
We defined in-hospital cardiac arrest to exclude events in the
emergency department. We excluded patients in a shockable rhythm
due to a finding of harm associated with mech-CPR use in this patient
group in the PARAMEDIC trial.7 This may be attributed to delays in
defibrillation in the mech-CPR group, although it has not been
replicated in other trials.16,17
For a team to be considered trained in the usemech-CPR, at least
two clinicians were required to be competent in device use. This
safeguardwas implementedasprevious researchhashighlighted that
mechanical chest compression device deployment can be associated
with prolonged chest compression pauses.18,19 We took the view that
ensuring at least two people present were competent in the
deployment process would mitigate this risk. Our approach was
informed by our preparatory simulation work.20
Study interventions
Following confirmation of cardiac arrest, all patients received man-
CPR. Following randomisation, the cardiac arrest team deployed the
mechanical chest compression device (mech-CPR- intervention
group) or continued to deliver manual CPR (man-CPR- control
group). All other treatments were delivered in accordance with
Resuscitation Council (UK) guidelines.21
A LUCAS-2 or LUCAS-3 mech-CPR device (Jolfe AB/Stryker,
Lund, Sweden) was deployed as soon as possible following
randomisation in participants randomised to mech-CPR. Teams were
trained using a pit-stop approach to minimise pauses in chest
compression delivery during device deployment through use of a two-
stagedeployment process.20 The targetmaximumchest compression
pause during each phase of deployment was ten seconds.
In patients randomised to the man-CPR arm, participants
continued to receive manual chest compressions. If available, teams
werepermitted to usea real-timeaudiovisual feedbackdevice to guide
man-CPR delivery.
Outcome measures
The primary outcome was the proportion of eligible patients
randomised during site operational recruitment hours.
Secondary outcomes included a range of measures, grouped as
study feasibility outcomes, patient outcomes, process outcomes, and
safety outcomes (Table S1 in Supplementary material). Our patient
follow-up included an assessment of survival, neurological outcome and
quality of life at six-months. Patient outcomes were selected to comply
with the Core Outcome Set for Cardiac Arrest (COSCA) statement.22
Recruitment and randomisation
Wedesigned the trial to facilitate recruitment 24-hadayby thehospital
cardiac arrest team.
On arrival of the mechanical chest compression device at the
cardiac arrest event, a trained clinician assessedpatient trial eligibility.
Eligible patients proceeded to randomisation. We used a sequentially
numbered sealed opaque tamper-proof envelope randomisation
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system. A single envelope was stored with each trial device. We
randomised eligible patients on an individual basis in a 3:1 ratio in
favour of the use of the mech-CPR.
We used an unequal randomisation ratio to increase clinician’s
potential exposure to mech-CPR use as this would better correlate
with exposure if devices were implemented in practice. Our
expectation was that this would help to optimise the deployment
process and safeguard participants against the potential harm
associated with prolonged chest compression pauses during
mechanical chest compression device deployment.
At the point that an envelope was opened, we categorised the
participant as being randomised for the intention-to-treat analysis.
One randomisation envelope was stored with each mechanical
device. Following envelope use, the next sequentially numbered
envelope was allocated to that device. The study statistician
generated the randomisation sequence, using the centre as strata
and randomblock sizes to ensure that a 3:1 allocationwasmaintained
for each strata. A staff member at the trial co-ordinating centre, who
was independent of the study team, packed the envelopes.
Blinding
We ensured allocation concealment through the use of an opaque
envelope system. We were unable to blind the clinical team as they
were required to deliver the clinical intervention. We did not
specifically seek to blind all site research teams as the randomisation
details were recorded in the patient’s medical record, but requested
that a blinded researcher support the participant to complete
discharge questionnaires. We also did not blind staff at the trial co-
ordinating centre as knowledge of allocated intervention was required
formonitoring of compliance. Participantswere initially blindedas they
would be unconscious due to cardiac arrest. We measured blinding
success through studyquestionnaires inwhich survivorswereasked if
they were aware of their allocated treatment intervention.
Consent
Patients were enrolled in the trial under a deferred consent model, as
approved by a Research Ethics Committee, in accordance with
English law. We approached participants, or a surrogate decision
maker, at the earliest reasonable opportunity following the cardiac
arrest event to seek consent for ongoing data collection.
Sample size and statistical analysis
Weplanned to recruit for a period of two-years or until we reached 330
participants, whichever came first. Feasibility trials typically recruit 25
50 patients per study arm.23 Our planned target of 330 participants
was to ensure sufficient precision in our estimate for the primary
outcome and to use the Cocks and Torgerson approach to determine
the statistical appropriateness of progression to an effectiveness
trial.24 For our trial, we estimated a sample size for an effectiveness
trial of 3554 patients, based on detecting a 3.5% absolute
improvement in 30-day survival at a power of 90% and a significance
level of 0.05. As such, we determined that 330 patients were required
for this feasibility trial (9% of 3554), after accounting for loss to follow-
up.24
For our statistical analysis, we describe categorical data as
frequencyandpercentageandcontinuousdataasmeanandstandard
deviation ormedianand interquartile range, dependingonnormality of
the data distribution. In our statistical plan, we described plans to
compare group outcomes, as we would for an effectiveness trial, by
describing risk ratio and 95% confidence interval or mean difference
and 95% confidence interval, as appropriate. In addition, for the
outcome of 30-day survival, we planned to compare groups using an
80%one-sided confidence interval, as described above. Analyses are
undertaken on an intention-to-treat basis.
Results
Over a two-year period (February 2017 to February 2019),
COMPRESS-RCT ran at five UK hospitals, of which three hospitals
recruitedpatients ona24/7 basis. Sites screeneda total of 936 cardiac
arrests, of which 662 occurred during site operational recruitment
hours (figure one). After excluding 432 events for patient reasons, we
randomised 127 (99 mech-CPR; 28 man-CPR) out of 230 potentially
eligible patients in cardiac arrest.
The proportion of patients randomised during operational recruit-
ment hours was 55.2% (95% confidence interval 48.5%61.8%). In
total, 38.6%participantswere randomised outside normal office hours
and 74.8% participants had analysable CPR quality data (Table 1;
Table S2 in Supplementary material). Some feasibility outcomes,
such as blinding success, are challenging to interpret due to the low
number of participants that reached that part of the trial.
The mean age of participants was 72 (95% CI: 69.974.9) years
and 59.8% (n =76) weremale (Tables 2 and 3). Most weremedical in-
patients (n = 90, 70.9%) with an initial rhythm of pulseless electrical
activity (n = 77, 60.6%). Using the GO-FAR score, most participants
(n = 80, 63.0%) were estimated to have 315% (average) chance of
survival with good neurological outcome based on pre-arrest
factors.25
Median arrest duration was 18 (IQR 1329) minutes, with median
time fromCPR start to randomisation of 6min (IQR 410). In patients
Table 1 – Study feasibility outcomes.
Outcome
Proportion of eligible patients randomised during site operational recruitment hours 55.2% (95% CI 48.561.8)
n = 127 of 230
Proportion of patients randomised outside of working hours 38.6% (95% CI 30.147.6)
n = 49 of 127
Proportion of patients/consultees agreeing to ongoing study participation 77.8% (95% CI 40.097.2)
n = 7 of 9
Percentage of patients with analysable chest compression quality data 74.8% (95% CI 66.382.1)
n = 95 of 127
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Table 2 – Participant characteristics.
Mech-CPR (n =99) Man-CPR (n =28) All cases (n = 127)
Age (years)  mean (95% CI) 72 (69.575.1) 73 (67.178.4) 72 (69.974.9)
Sex-male  n(%) 60 (60.6) 16 (57.1) 76 (59.8)
Weight (kg)  mean (95% CI) 71.5 (67.775.3) 77.6 (69.685.7) 73.0 (69.576.4)
Height (cm)  mean (95% CI) 167.5 (164.8170.3) 167.3 (162.7172.0) 167.5 (165.2169.8)
Baseline CPC  median (IQR) 1 (12) 1 (11) 1 (11)
Patient category  n(%)
Trauma 9 (9.1%) 2 (7.1%) 11 (8.7%)
Medical 72 (72.7%) 18 (64.3%) 90 (70.9%)
Elective/scheduled surgery 8 (8.1%) 2 (7.1%) 10 (7.9%)
Emergency/urgent surgery 9 (9.1%) 6 (21.4%) 15 (11.8%)
Outpatient 1 (1.0%) 0 (0.0%) 1 (0.8%)
Go-far score-likelihood of survival with good neurological outcome  n(%)
Very low 4 (4.0%) 0 (0.0%) 4 (3.2%)
Low 16 (16.2%) 5 (17.9%) 21 (16.5%)
Average 64 (64.7%) 16 (57.1%) 80 (63.0%)
Above average 15 (15.2%) 7 (25.0%) 22 (17.3%)
Missingness  weight 12 cases (11 mechanical, 1 manual); height 29 cases (24 mechanical, 5 manual).
Table 3 – Cardiac arrest characteristics.
Mech-CPR (n= 99) Man-CPR (n= 28) All cases (n = 127)
Initial rhythm  n(%)
PEA 59 (59.6%) 18 (64.3%) 77 (60.6%)
Asystole 36 (36.4%) 10 (35.7%) 46 (36.2%)
VF/VT 4 (4.0%) 0 (0%) 4 (3.2%)
Rhythm at time of randomization  n(%)
PEA 60 (60.6%) 18 (64.3%) 78 (61.4%)
Asystole 37 (37.4%) 10 (35.7%) 47 (37.0%)
VF/VT 2 (2.0%) 0 (0%) 2 (1.6%)
Arrest monitored  n(%) 42 (42.4%) 14 (50.0%) 56 (44.1%)
Arrest witnessed  n(%) 62 (62.6%) 17 (60.7%) 79 (62.2%)
Cardiac arrest location n(%)
Ward/Emergency Admissions Unit 84 (84.8%) 24 (85.7%) 108 (85.0%)
Coronary Care Unit 4 (4.0%) 1 (3.6%) 5 (3.9%)
Critical Care Unit 3 (3.0%) 2 (7.1%) 5 (3.9%)
Imaging Department 3 (3.0%) 1 (3.6%) 4 (3.1%)
Specialist Treatment Area 2 (2.0%) 0 (0%) 2 (1.6%)
Other 3 (3.0%) 0 (0%) 3 (2.4%)
Surface where CPR performed  n(%)
Foam mattress 59 (59.6%) 18 (64.3%) 77 (60.6%)
Air mattress 23 (23.2%) 5 (17.9%) 28 (22.1%)
Floor 6 (6.1%) 4 (14.3%) 10 (7.9%)
Other 6 1 (3.6%) 7
Unknown 5 (5.1%) 0 (0%) 5 (3.9%)
Mechanical device used  n(%) 71 (71.7%) 0 (0%) 71 (55.1%)
Adrenaline
Administered  n(%) 99 (100%) 26 (92.9%) 125 (98.4%)
Dosage (mg)  median (IQR) 3 (25) 3 (24) 3 (24)
Type of advanced airway  n(%)
Tracheal tube 33 (33.3%) 11 (39.3%) 44 (34.7%)
Supraglottic airway 50 (50.5%) 15 (53.6%) 65 (51.2%)
Not used 16 (16.2%) 2 (7.1%) 18 (14.2%)
Arrest timings  median (IQR)
Arrest duration (CPR start to CPR stop) 19 (1330) 18 (1025) 18 (1329)
CPR start to mechanical device arrival 6 (39) 4 (26) 5 (38)
CPR start to randomisation 7 (411) 5 (37) 6 (410)
CPR start to mechanical compressions 11 (715)  11 (715)
PEA  pulseless electrical activity; VF/VT  ventricular fibrillation/ventricular tachycardia.
Missingnesswitnessed2 cases (2mechanical); adrenaline dosage 3 cases (3mechanical); arrest duration 4 cases (4mechanical); time to device arrival 5 cases
(5 mechanical); time to randomisation 4 cases (4 mechanical); time to first mechanical compression 3 cases (3 mechanical).
R E S U S C I T A T I O N 1 5 8 ( 2 0 2 1 ) 2 2 8 2 3 5 231
randomised to mech-CPR, median time from CPR start to device
deployment was 11 (IQR 715) minutes. In the 99 patients
randomised to mech-CPR, 71.7% (n= 71) received mechanical chest
compressions. Themain reason for not usingmech-CPRwas returnof
spontaneous circulation prior to deployment (Fig. 1).
Data on mechanical device deployment were available for 62.9%
(n= 44) patients that received mech-CPR (Table 4). Mean time to
deploy thedevice backplate andupper unit of thedevicewas7.4 (95%
CI 6.08.9) and 9.8 (95% CI 7.911.8) seconds respectively. CPR
quality in both groups adhered, on average, to current guidelines
(Table 4; Table S3 in Supplementary material).26
ROSC was achieved in 27.6% (n= 35) participants (Table 5).
Survival to discharge, 30-days and six-months was observed in 3.9%
(n= 5), 4.7% (n =6), and 3.1% (n =4) participants respectively. All five
patients that survived to hospital discharge had a good neurological
outcome (n =5, 3.9%). Length of stay and quality of life outcomes are
reported in Table S4 in the Supplementary material.
Four device adverse events were reported, of which none were
categorised as serious. In two cases, the device did not start and
both events were attributed to human error. In one case, the device
did not restart after a rhythm assessment. Following an investigation
by the manufacturer and Medicines and Healthcare products
Regulatory Agency, a device-related cause could not be identified.
In all three cases, manual CPR was immediately recommenced. In
the fourth case, skin breakdown at the device compression point
was noted.
There were a number of protocol deviations during the study,
including the 28 participants randomised to mech-CPR who did not
receive the intervention (Fig. 1). Three participants were retrospec-
tively identified as having been ineligible at the point of randomisation:
two ofwhomwere in a shockable rhythmandonewhere an insufficient
number of trained team members were present. All were included in
the analysis in accordance with intention-to-treat principles. There
were two cases in which envelopes were used out of sequence.
Fig. 1 – Trial CONSORT flow chart.
232 R E S U S C I T A T I O N 1 5 8 ( 2 0 2 1 ) 2 2 8 2 3 5
Discussion
In this randomised feasibility trial comparing mech-CPR with manual-
CPR in the hospital setting, we recruited 127 patients over a two-year
period across five hospitals. We recruited 55% of potentially eligible
patients. We observed effective deployment of mech-CPR devices
and delivery of high-quality CPR across both study arms. Overall, 30-
day survival was 4.7%. Due to lower than planned recruitment, we
decided that it would not be informative to either statistically compare
groups or make use of the Cocks and Torgerson approach.24
Our rationale for undertaking a feasibility trial reflects limited
experience in both the UK and internationally of undertaking trials of
intra-arrest interventions in the setting of in-hospital cardiac arrest,
and the challenge of implementing a new health technology.14 Whilst
many UK hospitals own mechanical chest compression devices, use
is typically limited to specific locations, such as the emergency
department or cardiac catheter laboratory.12
Our trial demonstrated the feasibility of 24/7 recruitment to a
randomised controlled trial of an intra-arrest intervention across three
hospital sites. In the remaining two sites, 24/7 recruitment was
precluded by frequent changes in cardiac arrest team composition
and theassociatedneed to train a largenumberof individuals in device
use and trial procedures. This is an important finding that will inform
the design of future in-hospital trials.
In the specific context of a mech-CPR trial, we identified three key
challenges that would likely preclude progression to an effectiveness
trial, namely patient outcome; CPR quality; and overall recruitment.
Firstly, for patient outcome, we observed a lower than expected
hospital survival rate. Study recruits were patients in a non-shockable
rhythm that had not responded to initial resuscitation measures. The
implication of a low event rate is marked inflation of the sample size
required to reliably detect a difference between study arms. For
example, based on a baseline 30-day survival rate of 4.7%, a sample
size of over 20,000 patients would be required to detect a small 1%
difference in 30-day survival at 90% power and a significance level of
0.05.
Our original survival projection was based on registry data which
reported a hospital survival rate of approximately 10% in patients that
present inanon-shockable rhythm, comparedwith45% inpatients ina
shockable rhythm.1,27 Our observed 30-day survival rate of 4.7% is
likely explained by a combination of our target population (patients in a
Table 4 – CPR quality and device deployment metrics.
Mech-CPR (n= 99) Man-CPR (n= 28) All cases (n = 127)
CPR quality  mean (95% CI)
Compression depth (mm)a 59.2 (56.062.3) 59.1 (49.568.8) 59.2 (56.062.3)
Compression rate (/min) 109.0 (107.4110.7) 115.6 (110.5120.6) 110.4 (108.7112.1)
Flow-fraction 0.86 (0.90.9) 0.89 (0.90.9) 0.87 (0.90.9)
Device deployment  mean (95% CI)
Pause for backplate (seconds) 7.43 (6.08.9)  
Pause for upper part of device (seconds) 9.83 (7.911.8)  
Flow fraction in minute preceding first mechanical compression 0.68 (0.60.7)  
Missingness CC depth 61 cases (48 mechanical, 13 manual); CC rate 32 cases (24 mechanical; 8 manual); flow-fraction 32 cases (24 mechanical; 8 manual);
device deployment 27 cases.
a CC depth in mech-CPR arm describes CC depth prior to device deployment. CC depth in man-CPR describes depth over entire event.
Table 5 – Participant outcomes.
Mech-CPR (n= 99) Man-CPR (n= 28) All cases (n = 127)
ROSC 20min  n(%) 28 (28.3%) 7 (25.0%) 35 (27.6%)
Survival  n(%)
Hospital discharge  n(%)
4 (4.0%) 1 (3.6%) 5 (3.9%)
30 days  n(%)
5 (5.1%) 1 (3.6%) 6 (4.7%)
6-month  n(%)s
3 (3.0%) 1 (3.6%) 4 (3.1%)
Survival with good neurological outcome (CPC) n(%)
Discharge
4 (4.0%) 1 (3.6%) 5 (3.9%)
Survival with good neurological outcome (mRS) n(%)
Discharge
4 (4.0%) 1 (3.6%) 5 (3.9%)
6-months
1 (1.0%) 0 (0.0%) 1 (0.8%)
ROSC  return of spontaneous circulation; CPC  cerebral performance category; mRS  modified Rankin score.
Missingness  mRS at 6-months 2 cases (1 mechanical; 1 manual).
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non-shockable rhythm) and the timing of the intervention. Random-
isation occurred several minutes after arrest onset, by which point
patients had failed to respond to immediate treatments, such as chest
compressions, ventilation and oxygenation, and drug therapy.
Recruitment of patients earlier in their cardiac arrest would have
resulted in a higher survival rate.28,29 In studies of intra-arrest
interventions, time to intervention is an important determinant of
outcome. For example, an analysis of the PARAMEDIC-2 trial found
that adrenaline was most effective when given early in the cardiac
arrest.30 Cardiac arrest observational studies are subject to resuscita-
tion time bias as patients with longer cardiac arrests are most likely to
receive intra-arrest interventions, suchasdrugs,advancedairwaysand
mech-CPR.31 Thisbiashighlights the importanceof,wherever feasible,
robustly testing treatments in a randomised controlled trial.
In this trial, recruitment of patients earlier in the arrest would have
beenchallenging toachieveandreducedthereducedthe trial’sexternal
validity. Our approach was to strategically locate 23 devices across
each study site to best reflect practice in hospitals that already use
mechanical chest compression devices. Arrival of the device at the
arrest was required for randomisation. Our median reported time to
randomisationwassixminutes, although,as thiswasbasedonclinician
recollection of events, this likely reflects a best-case estimate.32 A
deployment model in which a device is located in each clinical area
would substantially increase cost, but may have limited effect on time-
to-deployment. For example, in an observational study of mechanical
device use in the cardiac catheter laboratory where the device was
immediately available, median time to device use was 7.4min.33
Secondly, the primary process by which it is proposedmechanical
chest compressiondevicesmight improveoutcome in cardiac arrest is
through the optimisation of chest compression delivery. This reflects
evidence that delivery of in-hospital CPR is often sub-optimal.3,34 A
key risk of mechanical chest compression device use are the pauses
associated with deployment.35 Our data on pauses during device
deployment compare favourably with published studies, including
those in highly optimised systems.18,19 However, in contrast to
previous studies, the high quality of CPR that we observed in the
manual chest compression arm meant that we did not observe any
separation of trial arms in relation to CPR quality.18 Two of the five
study hospitals routinely used real-time audiovisual CPR feedback
which exceeds the rate reported in the literature.36
Thirdly, our overall recruitment was lower than anticipated. This
was attributable to a number of system and patient factors, including
the challenge of delivering 24/7 recruitment at two of our sites, the
incidence of patients in shockable rhythm, and the decision to require
two clinicians present trained in device use. These are important
issues to consider when designing future trials.
Our study has a number of limitations. Firstly, despite the efforts of
site teams, we were unable to achieve our planned sample size. This
precluded key planned analyses, although we were able to base our
decision that an effectiveness trial is not feasible on other findings.
Secondly, we pragmatically selected study sites based on their
willingness to participate. We do not know how representative these
sites areof otherUKhospitals. Across these sites, therewasvariability
in use of real-time audiovisual feedback and previous experience with
mech-CPR, which reflects variability across UK hospitals.12 Thirdly,
compliance in the mech-CPR arm was 72%. Non-compliance was
typically due to ROSC, but a number of other reasons were recorded
including a decision that ongoing resuscitation was futile.
In this multi-centre feasibility randomised controlled trial, we
identified specific challenges that preclude progression to an
effectiveness trial of mech-CPR. These challenges were predomi-
nantly attributable to the challenge of implementing a new technology
safely in the context of a clinical trial. Our findings demonstrate that
recruitment to a randomised controlled trial of an intra-arrest
intervention is feasible and highlight key issues that will require
consideration in designing trials of other interventions.
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